Clinical and laboratory data at diagnosis in patients with AML (APL excluded) according to FLT3-ITD, NPM1, and age
| Number/median values . | No FLT3-ITD . | FLT3-ITD . | ||||||
|---|---|---|---|---|---|---|---|---|
| NPM1-mutated . | NPM1 wildtype . | NPM1-mutated . | NPM1 wildtype . | |||||
| <60 y . | 60-74 y . | <60 y . | 60-74 y . | <60 y . | 60-74 y . | <60 y . | 60-74 y . | |
| Number of patients | 100 | 144 | 386 | 475 | 95 | 109 | 83 | 69 |
| Sex, male/female, n | 48/52 | 68/76 | 223/163 | 290/185 | 41/54 | 52/57 | 46/37 | 32/37 |
| Median age, y | 51 | 67 | 47 | 67 | 51 | 67 | 44 | 67 |
| de novo AML, % | 92 | 85 | 89 | 69 | 91 | 87 | 96 | 75 |
| Intensive treatment, % | 100 | 94 | 97 | 89 | 95 | 97 | 100 | 96 |
| ECOG/WHO PS, % 0-II | 96 | 93 | 95 | 95 | 88 | 90 | 96 | 91 |
| Hemoglobin, g/L | 93 | 94 | 95 | 95 | 94 | 96 | 92 | 94 |
| Platelet count, ×109/L | 91 | 81 | 62 | 73 | 54 | 62 | 45 | 72 |
| WBC, ×109/L | 14.8 | 21.1 | 6.3 | 4.0 | 49.7 | 59.2 | 44.9 | 39.7 |
| Blood blast count, ×109/L | 3.7 | 5.9 | 2.6 | 0.8 | 23.4 | 22.0 | 17.2 | 13.7 |
| Bone marrow blasts, % | 50 | 59 | 50 | 42 | 70 | 72 | 70 | 54 |
| LDH, ukat/L (normal <4.2) | 7.0 | 6.4 | 5.9 | 5.2 | 10.1 | 10.1 | 10.1 | 9.7 |
| Death <28 days, % | 6.0 | 4.2 | 1.3 | 5.7 | 5.3 | 11.0 | 0 | 8.7 |
| Allogeneic SCT, % | 32 | 12.5 | 55 | 21.7 | 57 | 18.3 | 71 | 26.1 |
| Median OS, y | >12 | 3.3 | 10.1 | 1.3 | 1.9 | 2.0 | 1.9 | 1.0 |
| Number/median values . | No FLT3-ITD . | FLT3-ITD . | ||||||
|---|---|---|---|---|---|---|---|---|
| NPM1-mutated . | NPM1 wildtype . | NPM1-mutated . | NPM1 wildtype . | |||||
| <60 y . | 60-74 y . | <60 y . | 60-74 y . | <60 y . | 60-74 y . | <60 y . | 60-74 y . | |
| Number of patients | 100 | 144 | 386 | 475 | 95 | 109 | 83 | 69 |
| Sex, male/female, n | 48/52 | 68/76 | 223/163 | 290/185 | 41/54 | 52/57 | 46/37 | 32/37 |
| Median age, y | 51 | 67 | 47 | 67 | 51 | 67 | 44 | 67 |
| de novo AML, % | 92 | 85 | 89 | 69 | 91 | 87 | 96 | 75 |
| Intensive treatment, % | 100 | 94 | 97 | 89 | 95 | 97 | 100 | 96 |
| ECOG/WHO PS, % 0-II | 96 | 93 | 95 | 95 | 88 | 90 | 96 | 91 |
| Hemoglobin, g/L | 93 | 94 | 95 | 95 | 94 | 96 | 92 | 94 |
| Platelet count, ×109/L | 91 | 81 | 62 | 73 | 54 | 62 | 45 | 72 |
| WBC, ×109/L | 14.8 | 21.1 | 6.3 | 4.0 | 49.7 | 59.2 | 44.9 | 39.7 |
| Blood blast count, ×109/L | 3.7 | 5.9 | 2.6 | 0.8 | 23.4 | 22.0 | 17.2 | 13.7 |
| Bone marrow blasts, % | 50 | 59 | 50 | 42 | 70 | 72 | 70 | 54 |
| LDH, ukat/L (normal <4.2) | 7.0 | 6.4 | 5.9 | 5.2 | 10.1 | 10.1 | 10.1 | 9.7 |
| Death <28 days, % | 6.0 | 4.2 | 1.3 | 5.7 | 5.3 | 11.0 | 0 | 8.7 |
| Allogeneic SCT, % | 32 | 12.5 | 55 | 21.7 | 57 | 18.3 | 71 | 26.1 |
| Median OS, y | >12 | 3.3 | 10.1 | 1.3 | 1.9 | 2.0 | 1.9 | 1.0 |
ECOG/WHO, Eastern Cooperative Oncology Group/World Health Organization; LDH, lactic dehydrogenase; PS, performance status.